Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Solid Biosciences (Nasdaq: SLDB) announced that Bo Cumbo, President and CEO, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 10:30 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Solid Biosciences (Nasdaq: SLDB) announced that Bo Cumbo, President and CEO, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 10:30 AM ET. A live webcast will be available on the company Investor Events page, with a replay archived for 30 days.
Details
News Market Reaction – SLDB
On Feb 6, the day this news came out, SLDB closed 4.65% above the previous close.
Data tracked by StockTitan Argus for the Feb 6 session.
Key Figures
- Summit date
- February 12, 2026
- Guggenheim Emerging Outlook: Biotech Summit 2026 presentation date
- Presentation time
- 10:30 AM ET
- Scheduled time for Guggenheim summit presentation
- Webcast replay period
- 30 days
- Replay available on company’s Events page
Historical Context
-
Outlined 2026 outlook and clinical momentum across neuromuscular and cardiac programs.
-
Announced FDA Orphan Drug designation and existing Fast Track and Rare Pediatric status.
-
Dosed first participant in Phase 1b FALCON trial for SGT-212 in Friedreich’s ataxia.
-
Announced J.P. Morgan Healthcare Conference presentation with webcast access for investors.
-
Reported inducement grant of 7,000 RSUs to a new employee under stock plan.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
neuromuscular medical
cardiac medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHARLESTOWN, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 10:30 AM ET.
A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page.
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic neuromuscular and cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.